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Abstract: Sphingolipids are a class of lipids that have important functions in a variety of cellular processes such as, differentiation, pro-
liferation, senescence, apoptosis and chemotherapeutic resistance. The most widely studied bioactive shingolipids include ceramides, di-
hydroceramide (dhCer), ceramide-1-phosphate (C1P), glucosyl-ceramide (GluCer), sphingosine and sphingosine-1-phosphate (S1P). Al-
though the length of fatty acid chain affects the physiological role, ceramides and sphingosine are known to induce apoptosis whereas 
C1P, S1P and GluCer induce proliferation of cells, which causes the development of chemoresistance. Previous studies have implicated 
the significance of bioactive shingolipids in oncogenesis, cancer progression and drug- and radiation-resistance. Therefore, targeting the 
elements of sphingolipid metabolism appears important for the development of novel therapeutics or to increase the effectiveness of the 
current treatment strategies. Some approaches involve the development of synthetic ceramide analogs, small molecule inhibitors of en-
zymes such as sphingosine kinase, acid ceramidase or ceramide synthase that catalyze ceramide catabolism or its conversion to various 
molecular species and S1P receptor antagonists. These approaches mainly aim to up-regulate the levels of apoptotic shingolipids while 
the proliferative ones are down-regulated, or to directly deliver cytotoxic sphingolipids like short-chain ceramide analogs to tumor cells. 
It is suggested that a combination therapy with conventional cytotoxic approaches while preventing the conversion of ceramide to S1P 
and consequently increasing the ceramide levels would be more beneficial. This review compiles the current knowledge about sphin-
golipids, and mainly focuses on novel agents modulating sphingolipid pathways that represent recent therapeutic strategies for the treat-
ment of cancer. 
Keywords: Bioactive sphingolipids, cancer, ceramides, ceramide synthase, ceramide kinase, drug resistance, glucosylceramide, glucosylce-
ramide synthase, sphingosine kinase-1, sphingosine-1-phosphate, sphingosine-1-phosphate receptor, cancer treatment. 
1. INTRODUCTION 
Sphingolipids (SLs) are important constituents of eukaryotic 
cells and are also found in the bacterial genus Sphingomonas. They 
are composed of an amide-linked fatty acid chain and amino alco-
hol sphingosine base. Various groups linked to the sphingosine 
backbone determine the type of the sphingolipid. Since their dis-
covery by J. L. W. Thudichum in 1876, sphingolipids have been 
considered to be essential solely for structural purposes in cells. 
However, intensive research showed that they have major roles in 
signaling events that regulate various cellular activities [1-3]. Ce-
ramide (Cer) and sphingosine-1-phosphate (S1P) are the two main 
sphingolipids, and are involved in important cellular processes such 
as cell proliferation [4], differentiation [2, 5], apoptosis [6], motility 
[7], angiogenesis [8], protein synthesis [9], stress responses [10, 
11], carbohydrate metabolism [12], and intracellular trafficking 
[12]. Other widely studied sphingolipids include dihydroceramide 
(dhCer), ceramide-1-phosphate (C1P) and sphingosine (Sph) [13, 
14]. Ceramide and sphingosine are typically known to induce cell 
growth arrest and cell death whereas other glycosylated or phos-
phorylated elements of sphingolipid family including S1P or C1P 
influence cellular proliferation, survival and drug resistance. As 
sphingolipids are involved in the regulation of important signalling 
pathways, altered sphingolipid metabolism may cause pathologic 
conditions and contribute to cancer progression [15]. Previous stud-
ies have shown the significance of bioactive sphingolipids in onco-
genesis, cancer progression and drug- and radiation-resistance [16]. 
Therefore, targeting the elements of sphingolipid metabolism ap-
pears to be important for the development of novel therapeutics. 
This review compiles the current knowledge about sphingolipid 
metabolism and cellular roles of bioactive sphingolipids, and 
mainly focuses on novel agents modulating sphingolipid pathways 
that represent recent therapeutic strategies for the treatment of can-
cer. Recent evidences explaining the roles of these lipids in  
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tumorigenesis, tumor development and cancer therapeutics will be 
discussed. 
1.1. Sphingolipid Metabolism 
Ceramide is the central element of sphingolipid metabolism and 
is composed of a long-chain sphingoid base, sphingosine, contain-
ing various numbers of carbon atoms in combination with a fatty 
acid chain. It is known that different stimuli such as interleukin 
(IL)-1, tumor necrosis factor-? (TNF-?), Fas ligand, ionizing radia-
tion [17], oxidative stress [18], and chemotherapeutics [19] induce 
the production of ceramide. Ceramide can be generated by two 
major mechanisms Fig. (1). The first one is the de novo pathway, an 
anabolic pathway, which takes place on the cytosolic surface of the 
endoplasmic reticulum (ER) and possibly in the perinuclear mem-
brane and mitochondria-associated membranes known as ER-
associated membranes [20]. In this pathway, ceramide is firstly 
synthesized from serine and palmitoyl-CoA to form 3-keto-
dihydrosphingosine through the action of serine palmitoyltrans-
ferase (SPT) [21-24]. Subsequent steps involve the conversion of 3-
keto-dihydrosphingosine to dihydrosphingosine (sphinganine) 
which is then N-acylated to dihydroceramide (dhCer) or Cer by 
dhCer synthases [25]. Six mammalian genes that encode (dh)Cer 
synthase have recently been cloned and called longevity assurance 
homolog-1 of yeast Lag1 (LASS1-6)/Cer synthase (CerS1-6). Dif-
ferent CerS genes are responsible for the synthesis of different 
length of ceramides. CerS1, for example, synthesizes C18-
ceramide, whereas CerS2 and CerS4 induce the production of C24- 
and C22- ceramides, respectively [26]. DhCer is then desaturated 
by dhCer desaturase, to generate Cer in the last step of de novo 
synthesis pathway [20, 27].  
Another mechanism known as the “sphingomyelin cycle” is re-
sponsible for the production of ceramide [28] and involves the hy-
drolysis of plasma membrane sphingomyelin (SM) to ceramide and 
phosphorylcholine through the action of sphingomyelinase (SMase) 
enzyme [29-31]. Various SMases have been characterized accord-
ing to their pH optima and subcellular localization: lysosomal acid 
SMase (aSMase), neutral magnesium-dependent SMase (nSMase), 
zinc-dependent secretory SMase, and alkaline SMase [32]. There is 
evidence suggesting that stimulation of neutral and acidic SMases 
has a major role in cell cycle arrest and apoptosis [33, 34]. The best 
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identified enzyme is lysosomal A-SMase, the deficiency of which 
causes Niemann-Pack disease types A and B. Sphingomyelin syn-
thase can also be catalyzed producing sphingomyelin from cera-
mide in a process where phosphatidylcholine is used and diacyl-
glycerol is liberated [35]. For SM production, ceramide is trans-
ported from the ER to the Golgi by a ceramide transfer protein 
(CERT) [36, 37]. 
Ceramide can also be generated by the breakdown of gly-
cosphingolipids, a mechanism called the “salvage pathway”. In this 
mechanism, the terminal hydrophilic portions of glycosphingolipids 
are sequentially removed and catalyzed by a series of specific hy-
drolases. Glucosylceramide (GluCer) and galactosylceramide (Gal-
Cer) are the intermediate products which are subsequently hydro-
lyzed by specific ?-glucosidases and galactosidases to produce Cer 
[38]. GluCer is generated by GluCer synthase (GCS) in the Golgi, 
which serves as a precursor for the synthesis of complex gly-
cosphingolipids in the same subcellular compartment [39]. In this 
reaction, ceramides are carried from ER to Golgi by vesicle bud-
ding without the support of a protein transporter [40]. However, the 
synthesis of complex glycosphingolipids (e.g. gangliosides) occurs 
in the luminal side of the Golgi. Therefore, the transport of GluCer 
from the cytosolic surface to the inside of the Golgi is carried out 
by the ABC transporter, P-glycoprotein (also known as MDR1) 
[41]. GluCer can be converted back to ceramide by glucosylcera-
midase [42]. 
Ceramide produced through the de novo pathway or sphin-
golipid recycling can be reversly catalyzed into sphingosine by 
ceramidases (CDase) [43, 44]. Similar to SMases, CDases have also 
been classified according to their pH optimum and subcellular lo-
calization as acid CDases, neutral CDases and alkaline CDases 
[45]. Sphingosine is a bioactive lipid, which promotes apoptosis or 
inhibits cell proliferation, depending upon the cell type [46]. Sphin-
gosine is then phosphorylated by sphingosine kinase-1 and -2 (SK-1 
and SK-2) producing the mitogenic signalling lipid, sphingosine-1-
phosphate (S1P) [47]. Sphingolipids including ceramide, sphingos-
ine and S1P can be converted back to sphingosine by lipid phospha-
tases [48, 49]. Additionally, S1P can be irreversibly cleaved by the 
enzyme S1P lyase (SPL) to generate non-sphingolipids, ethanola-
mine phosphate and hexadecenal [50]. This step is the only exit 
pathway from the sphingolipid pathways.  
1.2. Cellular Roles of Bioactive Sphingolipids 
Ceramide is the most studied bioactive sphingolipid and is 
mainly known to be a tumor-suppressor lipid acting not only in 
intracellular but also in extracellular processes. Cer is best known to 
be involved in programmed cell death (apoptosis). Additionally, it 
is reported to influence the regulation of cell growth, differentiation 
[28], proliferation [51], senescence [52], and necrosis [53]. In order 
to exert regulative functions in the cellular processes, ceramides 
interact with protein kinases and phosphatases. Long-chain cera-
mides activate protein phosphatase-1 (PP1) and protein phospha-
tase-2A (PP-2A), which are therefore known as ceramide-activated 
protein phosphatases (CAPPs) [54]. Activated CAPPs are responsi-
ble for transmitting the signal to downstream targets including reti-
noblastoma protein (Rb), cyclin-dependent kinases (CDKs) and 
Bcl-2 family members [55, 56]. Ceramide induces intrinsic apop-
 
Fig. (1). Bioactive sphingolipid metabolism. CerS (LASS), ceramide synthase; CDase, ceramidase; DES, dihydroceramide desaturase; SMS, sphingomyelin 
synthase; SMase, sphingomyelinase; GCS, glucosyl-ceramide synthase; GCase, glucosyl ceramidase; CK, ceramide kinase; S1P, sphingosine-1-phosphate; 
SPPase, S1P phosphatase; SK, sphingosine kinase; C1PP, ceramide-1-phosphate phosphatase. 
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totic pathway via the regulation of cytochrome c release and the 
loss of mitochondrial membrane potential [57]. Furthermore, cera-
mides are known to affect Akt [21], protein kinase C (PKC) [58], 
phospholipase D, raf-1 [59], and the kinase-suppressor of Ras [60], 
and significantly alter the level of phosphorylation of various key 
substrates. Cathepsin D is known to be a binding target for Cer, 
which may control the actions of lysosomally generated Cer [61].  
Most chemotherapeutic drugs have been shown to increase the 
levels of ceramide and subsequently, endogenous ceramide pro-
duced after cytotoxic stimuli and chemotherapy treatment induces 
apoptosis. In a study by Bose et al. [19], daunorubicin-induced 
apoptosis of leukemia cells was observed due to increased levels of 
ceramide. In another study, elevated levels of ceramide and sphin-
ganine were observed in HL60 leukemia cells following treatment 
with H2O2 [62]. Combination of paclitaxel and tamoxifen was 
shown to increase ceramide levels and overcome drug resistance in 
ovarian adenocarcinoma [63]. Defective generation of ceramide 
caused resistance of PC3 prostate cancer cells to chemotherapy 
[64]. 
An alternative way to elevate the levels of endogenous cera-
mide within the cell via anticancer agents is administration of ex-
ogenous short-chain ceramides. Exogenous ceramide analogs were 
shown to induce apoptosis in several types of tumor cells [65-67]. 
Encapsulation of exogenous short-chain ceramides (C2-, C6-, C8-
ceramide) into nanoliposomal formulations for systemic delivery 
has been studied and results have shown that cell death induction is 
achieved in multiple syngeneic and xenograft cancer models, and 
no systemic side effects are observed [68-71]. Besides using short-
chain ceramide species, several studies have focused on utilization 
of novel ceramide analogs which also induce apoptosis in human 
tumor cells. These analogs and small molecule inhibitors of en-
zymes such as sphingosine kinase, acid ceramidase or ceramide 
synthase and mimetics that are implicated in cancer biology will be 
discussed in detail in further sections of the manuscript. 
Ceramide-mediated apoptosis is vital both for cancer cell death 
and for maintaining homeostasis in healthy cells since Cer is con-
sidered to be present in several healthy cells including macrophages 
and developing embryos [72-73]. Moreover, a recent study under-
taken in human head and neck carcinomas has indicated that cera-
mides with long fatty acid chains such as C18- and C16- exert 
proapoptotic and prosurvival responses [74]. This explains the sig-
nificance of ceramides in tumors, and defines the complexity of 
sphingolipid metabolism and its dysregulation in malignancy.  
Sphingosine-1-phosphate, a product of sphingosine kinase, is 
known to be an anti-apoptotic, tumor-promoting lipid involved in 
the regulation of survival, proliferation, cell growth, cell migration, 
inflammation, angiogenesis, and vasculogenesis [75]. S1P binds to 
G-protein-coupled receptors (GPCRs) (S1P receptors) on the cell 
surface to elicit cell responses [76]. These S1P receptors have been 
categorized into a group of five GPCRs identified as S1P1-S1P5 [7, 
77]. S1P signalling through these GPCRs has been shown to be 
atypical in different cancer models [78]. For example, the S1P1 
receptor is highly expressed on the surface of malignant lymphoma 
cells [79] whereas the invasion of glioma cells is shown to be en-
hanced by the expression of the S1P2 receptor [80]. Levels of S1P 
are closely related to resistance to apoptotic cell death in cancer; 
therefore S1P shows antagonizing effects to those of Cer [81]. The 
cellular ceramide/S1P ratio, also described as the “S1P Rheostat” 
[82, 83], has been proved to be a critical balance determining the 
survival or death of mammalian cells [84]. Elevated levels of 
SK/S1P have been detected in various cancer and tumor tissues. 
Overexpression of SK1 in MCF-7 breast cancer cell line was ob-
served to inhibit apoptosis induced by anticancer agents, including 
sphingosine and TNF-? [85]. In addition, S1P was shown to acti-
vate p38 MAPK and ERK pathways which specifically increase the 
proliferation of tumor cells and potentiates cell survival [86]. S1P 
also increases the levels of platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor (VEGF) which are known to 
highly affect tumor angiogenesis and cancer cell migration [87-89]. 
In detail, it was shown that the S1P-induced VEGF mRNA expres-
sion was dependent on increased phosphorylation of transcription 
factors such as phospholipase-C (PLC), Akt, extracellular signal-
regulated kinases (ERK), AP1, phosphatidylinositol-3 kinase 
(PI3K) and p38 mitogen-activated protein kinase (MAPK). These 
results suggest that VEGF receptor gets activated in either autocrine 
or paracrine fashion following the up-regulation of the expression 
of VEGF. Therefore, it is postulated that VEGF is likely to have an 
important role in SP1-mediated cell migration and mitogenesis [88].  
SK1 and SK2 were shown to have opposing effects on the regu-
lation of ceramide biosynthesis [90]. Contrary to SK1, SK2 was 
found to be proapoptotic through calcium-mediated apoptosis. It 
was thought that cellular location of the S1P product determines its 
function.  
Sphingosine, like ceramide, is a growth inhibitory and pro-
apoptotic sphingolipid, which has been studied in different cell 
lines including both cancerous and healthy cells [91]. Apoptosis 
induced by sphingosine was shown to be dependent on cytochrome-
c release from mitochondria and also through the inhibition of PKC 
[92, 93]. 
The sphingolipid metabolite, C1P, is formed after phosphoryla-
tion of ceramide by the ceramide kinase (CerK), and the reverse 
reaction is catalyzed by C1P phosphatase [94]. C1P has opposing 
regulatory roles when compared to ceramides, and contributes to 
cancer development by stimulating DNA synthesis and suppressing 
programmed cell death [95]. PKC was shown to be essential for the 
proliferative effects of C1P [96]. In a study, apoptosis in macro-
phages was observed to be inhibited by C1P via suppression of de 
novo ceramide synthesis pathway [97]. In macrophages, PI3 kinase, 
JNK and ERK1/2 pathways were mediated by C1P in order to show 
pro-survival effects [98]. Additionally to the cell cycle control, C1P 
was also found to be involved in mammalian inflammatory re-
sponses [7]. 
DhCer is an intermediate in the de novo ceramide synthesis 
pathway. Several studies have provided evidence that dhCer is an 
important bioactive sphingolipid. Induction of autophagy following 
treatment with exogenous dhCer analogs was demonstrated on both 
gastric and prostate cancer cell lines [99]. DhCer is also assumed to 
play a role in growth inhibition and hypophosphorylation of Rb 
protein [100]. 
GluCer, which is converted from ceramide by GCS, is an in-
termediate element in the sphingolipid metabolism [101]. In several 
studies, it has been shown that GluCer has growth promoting func-
tions, and it is important in chemotherapeutic drug resistance [102, 
103]. GluCer was detected to directly upregulate the expression of 
MDR1 via cSrc and ?-catenin pathways producing chemoresistant 
cancer subtypes [104]. GluCer levels were found to be elevated in 
the resistant type of tumors [105, 106].  
2. MOLECULES THAT SPECIFICLY INHIBIT BIOLOGI-
CALLY ACTIVE SPHINGOLIPIDS 
2.1. Glucosyl Ceramide Synthase Inhibitors 
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) 
is a widely used agent in the inhibition of GCS activity in various 
types of cancer cells Fig. (2). It has been reported that PPMP inhib-
its GCS in N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide)-
sensitive and –resistant CCRF-CEM acute lymphoblastic leukemia 
cells [107]. PPMP has been also reported to have GCS inhibitory 
effects on adriamycin-resistant K-562/A02 chronic myeloid leuke-
mia cells and on doxorubicin-resistant MCF-7-AdrR breast cancer 
cells [108, 109]. In these cells, GCS inhibition via PPMP treatment 
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increases vinblastine uptake, decreases expression levels of MDR1 
gene and P-glycoprotein protein, which are important in the devel-
opment of multidrug resistance. Similarly, these effects of PPMP 
have been also reported in vinblastine-resistant KB-V0.01 cervix 
cancer cells [109]. Moreover, in PPMP-treated HL-60 human acute 
promyelocytic leukemia and U-937 human histiocytic lymphoma 
cells, PPMP prevents daunorubicine-induced apoptosis, and also 
PPMP treatment results in an increase in ceramide galactosylation 
rather than an increase in ceramide levels [110]. In human neuro-
blastoma, lung, melanoma, colon, breast, and also prostate cancer 
cells, PPMP has been reported to increase the cytotoxic effects of 4-
HPR and tamoxifen through p53-independent and caspase-
independent pathways [111]. Furthermore, it has been shown that 
PPMP treatment in CD4- and several chemokine receptor- bearing 
osteosarcoma cells results in suppression of glycosphingolipid syn-
thesis and a decrease in HIV infection [112]. In 2007, Chan et al. 
reported that co-treatment with PPMP increased the cytotoxic ef-
fects of C6:ceramide on MDA-MB-435 human breast cancer cells. 
They also showed that the treatment of MDA-MB-435 cells with 
PPMP alone results in apoptosis by generating reactive oxygen 
species [113]. 
The other commonly used GCS inhibitor in cancer treatment is 
DL-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol 
(PDMP) Fig. (2). Like PPMP, PDMP is also used in several types 
of cancer. Our studies have indicated that PDMP inhibits GCS ac-
tivity and triggers apoptosis in cancer cells. We have also shown 
that PDMP inhibits GCS expression, and increases the cytotoxic 
and apoptotic effects of resveratrol on K-562 human chronic mye-
loid leukemia, and HL-60 human acute promyelocytic leukemia 
cells [114, 115]. In addition, we have demonstrated that PDMP is 
also effective in sensitizing K-562-IMA imatinib-resistant human 
chronic myeloid leukemia cells to imatinib [116]. Furthermore, 
PDMP together with nilotinib have demonstrated significant syner-
gistic apoptotic effects on K-562 cells [117]. We also showed that 
PDMP increases the cytotoxic effects of dasatinib on K-562 and 
Meg-01 human chronic myeloid leukemia cells [118]. Moreover, it 
has been revealed that there are synergistic cytotoxic and apoptotic 
effects between PDMP and docetaxel on DU-145 and PC-3 human 
prostate cancer cells [119]. In human U87-MG glioma cells with 
active p53, PDMP triggered the activation of caspases induced by 
radiation via accumulating intracellular ceramide [120]. According 
to a recent study, PDMP treatment of drug-resistant CML T315I 
mutant cells increases the sensitivity of these cells to imatinib, 
nilotinib, or GNF-2, an agent used for the inhibition of BCR/ABL 
in vivo and in vitro, and causes initiation of apoptosis through GSK-
3 activation [121]. PDMP significantly suppressed VEGF- and 
FGF-mediated angiogenesis in HUVEC and HAEC, human umbili-
cal vein endothelial cells and human aortic endothelial cells, respec-
tively, in vitro, and in nude mice bearing colon cancer [122]. Inter-
estingly, PDMP treatment together with paclitaxel results in abnor-
mal cell cycle progression with hyperploidy rather than ceramide 
accumulation-triggered apoptosis in Neuro-2a murine neuroblas-
toma cells [123]. 
D,L-threo-1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-
propanol (PPPP) is the other GCS inhibitor. It has been reported 
that PPPP is less effective than PDMP in terms of triggering apop-
tosis in HepG-2 human hepatoma cells [124]. PPPP has been also 
reported as an effective GCS inhibitor in human neuroblastoma 
cells [125]. 
Genz-123346 is another GCS-inhibiting agent used in studies 
Fig. (2). A study reporting the chemosensitization effects of Genz-
123346 in different cancer cells, including HCT-15 human colon 
carcinoma cells, HepG-2 human hepatocellular carcinoma cells, and 
KB3-1 human cervical cancer cells, showed that Genz-123346 is a 
substrate for P-gp [126]. 
Bieberich et al. [127] reported that N-butyldeoxynojirimycin 
(NB-DNJ) has an inhibitory effect on GCS activitiy Fig. (2). 
Treatment of neuroblastoma cells resulted in less ceramide accumu-
lation and cell death, suggesting that NB-DNJ is less cytotoxic and 
apoptotic than PDMP [127]. In addition, treatment of MEB-4 mur-
ine melanoma cells with NB-DNJ resulted in inhibition of GCS 
activitiy, but this treatment did not cause ceramide accumulation or 
cellular toxicity [128]. Moreover, it was shown that NB-DNJ inhib-
its GCS activity, while it has no chemosensitivity effect on neuro-
blastoma cells [129]. 
OGT2378 is an agent that inhibits GCS function Fig. (2) [130]. 
In murine models with melanoma, OGT2378 decreased tumor size, 
and showed no cytotoxic and apoptotic effects on MEB-4 mela-
noma cells. Additionally, it has been reported that OGT2378 is 
biologically active, and a well tolerated agent in in vivo system 
[131]. 
2.2. Sphingosine Kinase Inhibitors 
One of the commonly used SK inhibitors is 2-(p-hydroxy 
anilino)-4-(p-chlorophenyl) thiazole, which is known as SKi Fig. 
(3). SKi inhibiting both SK-1 and SK-2 function, has cytotoxic and 
apoptotic effects on several cancer cells [132]. In multidrug resis-
tant breast cancer cells, it decreases cellular proliferation and trig-
gers apoptosis via switching NF?B signaling pathway [133]. SKi is 
maintained in blood for eight hours in mice after oral administra-
tion, and it decreases tumor size [134]. Additionally, according to 
our studies SKi is significantly effective in undergoing apoptosis 
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and chemosensitizing several types of cancer cells, including leu-
kemia and prostate cancer to different anticancer agents. We also 
found that SKi inhibits SK expression, and increases the cytotoxic 
and apoptotic effects of resveratrol on K-562 human chronic mye-
loid leukemia, and HL-60 human acute promyelocytic leukemia 
cells [114, 115]. In addition, SKi together with nilotinib have dem-
onstrated significant synergistic apoptotic effects on K-562 cells 
[117]. According to our studies, SKi increases the cytotoxic effects 
of dasatinib on K-562 and Meg-01 human chronic myeloid leuke-
mia cells [118]. It has also been reported that there are synergistic 
cytotoxic and apoptotic effects between PDMP and docetaxel on 
DU-145 and PC-3 human prostate cancer cells [119]. 
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-
ylmethyl) amide (ABC294640) is a new selective SK-2 inhibitor 
that suppresses cell proliferation, increases cellular apoptosis, and 
decreases tumor size in mice bearing kidney carcinoma, hepatoma, 
or mammary adenocarcinoma Fig. (3) [135, 136]. ABC294640 
causes not only apoptosis but also autophagy in different cancer 
cells, including MDA-MB-231 mammary adenocarcinoma, PC-3 
prostate cancer, and also A-498 kidney carcinoma [137].  
(2R,3S,4E)-N-methyl-5-(4?-pentylphenyl)-2-aminopent-4-ene-
1,3-diol (BML258) inhibits selectively SK-1 activity, but not SK-2 
Fig. (3). In vitro studies with U937 human histiocytic leukemia and 
Jurkat acute T-cell leukemia cells, and in vivo studies with leukemic 
blasts obtained from acute myelogenous leukemia (AML) patients 
revealed that BML-258 has significant cytotoxic and apoptotic 
effects on these cells [138]. 
Fingolimod (FTY720) is another important SK inhibitor. It is 
effective on both SK-1 and SK-2 activity [139]. Structural variants 
of FTY720 also inhibit SK activity effectively. (S)-FTY720 
vinylphosphonate inhibits SK-1 function through an uncompetitive 
way in cancer cells [140]. (R)-FTY720-OMe also specifically 
inhibits the function of SK-2. In MCF-7 human breast cancer cells, 
(R)-FTY720-OMe has been reported to suppress the synthesis of 
DNA and repress actin rearrangement, which results in the 
prevention of metastasis Fig. (3) [141].  
Dimethylsphingosine (DMS) is another agent used as an SK in-
hibitor Fig. (3). According to a recent study, DMS treatment of 
LOVO colon cancer cells decreases the ability of cells in prolifera-
tion and invasion, while it triggers apoptosis [142]. In addition, 
DMS-mediated decrease in cell viability and invasion, and increase 
in apoptosis may be triggered by the activation of p38 and 
SAPK/JNK signaling pathways [143]. 
PF543, a novel selective SK-1 inhibitor, inhibited SK-1 activity 
in a competitive manner with sphingosine, but it was not effective 
on cell proliferation or survival in 1483 head and neck cancer cells 
Fig. (3) [144].  
Safingol, L-threo-dihydrosphingosine (DHS) is the first agent 
used in clinical trials to inhibit sphingosine kinase activity Fig. (3) 
[145]. In vivo and in vitro studies indicated that safingol is more 
effective when it is used together with other chemotherapeutic 
agents than alone. When it is used alone, safingol triggers auto-
phagy via PI3K signaling, whereas it enhances anticancer effects of 
the agents, such as cisplatin and doxorubicin [146, 147]. Treatment 
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of the patients having solid tumors with safingol in combination 
with cisplatin results in hepatic toxicity in a dose-dependent man-
ner, but this effect is reversible [145]. 
2.3. Sphingosine-1-Phosphate Receptor Inhibitors 
FTY-720 is an FDA-approved immunosuppresant for the 
treatment of multiple sclerosis. Besides having SK-1 and SK-2 
inhibitory effect, FTY-720 also modulates S1P receptors-except 
S1PR2 [148]. SK-2 converts FTY-720 to (S)-FTY720 phosphate in 
vivo, and (S)-FTY720 phosphate can bind S1PR1, 3, 4, and 5, and 
acts as an antagonist for S1PR1 in terms of functionality [149]. 
Furthermore, FTY-720 is capable of suppressing metastatic activity 
in mice with melanoma or breast cancer, and causing a reduction in 
cellular proliferation, and also triggering apoptosis by preventing 
the formation of new blood vessels [139, 150].  
Kennedy et al. [151] reported that 1-(hydroxymethyl)-3-(3-
octylphenyl) cyclobutane (VPC03090), an analog of FTY-720, acts 
as antagonist for S1PR1 and S1PR3. VPC03090-P, converted from 
VPC03090 through the phosphorylation by SK-2, causes a reduc-
tion in tumor growth in mice with mammary cancer, and its oral 
bioavailability is determined to be 30 hours. 
Although the agents mentioned above inhibit S1PR activity, it 
is known that all cancer cells as well as all cancer patients express 
S1PRs in a unique and different level. Therefore, in order to gain a 
successs in cancer therapy via S1PR inhibition, all of the S1PRs 
must be blocked [152]. For this reason, using anti-S1PRs mono-
clonal antibodies is a more effective way in targeting all S1PRs and 
preventing the ligands to bind their receptors. LT1002, known as 
Sfingomab, is a mouse S1PR monoclonal antibody. In 2006, Vis-
entin et al. firstly characterized sfingomab, and reported that sfin-
gomab treatment results in decreased tumor progression, cellular 
proliferation, tumor angiogenesis and migration, and prevents ovar-
ian cancer, breast carcinoma, and lung adenocarcinoma cells to 
escape from apoptotic signals [153]. O’brien et al. [154] developed 
a humanized S1P antibody, LT1009, known as sonepcizumab. 
Sonepcizumab treatment of SKOV3 human ovarian carcinoma cells 
resulted in prevention of binding of S1P to S1PRs, and by this way, 
the prevention of S1P-triggered release of IL-8 cytokine which is 
important in angiogenesis and metastasis [154]. Phase I clinical 
trials demonstrated that sonepcizumab treatment of patients with 
solid tumors such as colorectal, breast, ovarian, renal, prostate, and 
head-and-neck cancer resulted in stable disease, and no disease 
progression was observed for approximately 8-12 months in most 
of the patients. Additionally, sonepcizumab treatment was well-
tolerated in cancer patients, and it was demonstrated to be important 
in trafficking of lymphocytes. S1P activity was found to increase 
lymphocyte number, while sonepcizumab treatment was shown to 
decrease it [152, 155].  
2.4. Ceramidase Inhibitors 
Neutral and acid ceramidase activities were found to be in-
creased in tumors as compared to normal cells [156-158]. There-
fore, inhibition of ceramidases is an alternative strategy to induce 
ceramide accumulation and apoptotis in cancer cells.  
Currently, different ceramidase inhibitors are being developed 
as anticancer drugs, either alone or in combination with other thera-
pies Fig. (4). An alkaline ceramidase specific inhibitor called 
1S,2R-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol (D-
erythro-MAPP) was shown to cause growth suppression and cell 
cycle arrest in HL-60 human promyelocytic leukemia cells [159]. 
On the other hand, D-MAPP also fuctions as a moderate but selec-
tive inhibitor of acid ceramidase in human melanoma and HaCat 
keratinocytes in which D-MAPP induces apoptosis by increasing 
endogeneous ceramide levels [160]. According to another report, 
D-MAPP in combination with DL-PDMP (a specific inhibitor of 
glucosylceramide synthase) and imipramine (an amphiphilic amine 
responsible for lipid turnover in biological membranes) increased 
the apoptotic effect of ionizing radiation in Jurkat cells [161] and 
sensitized radioresistant SQ20B squamous carcinoma cells to ?-rays 
[162]. Inhibiting the acid ceramidase is an another potential strategy 
for cancer therapy since it is upregulated in several cancers and 
confers resistance to chemo- and radiotherapy [163, 164]. 1R,2R-d-
erythro-2-N-myristoylamino-1-nitrophenyl-propan-1,2-diol (B13), 
an acid ceramidase inhibitor, increased ceramide levels and induced 
apoptosis in SW-403 human metastatic colorectal cancer cells but 
not in normal cells. Morever, B13, also called D-NMAPPD, pre-
vented tumor growth in nude mice in which metastatic colon cancer 
was established by using SW-403 and Lovo human colon cancer 
cells [165]. Apoptotic effects of B13 were shown on cultured 
LNCaP and PC-3 prostate cancer cells. In addition, treatment of 
androgen-insensitive prostate cancer xenografts with B13 showed 
that B13 increased sensitivity of tumors to radiation and caused a 
significant reduction in tumor size [166]. Acid ceramidase inhibi-
tion has been also triggered by N-oleoylethanolamine (NOE) which 
is responsible for the initiation of antiproliferative effects in a vari-
ety of cancer cells [167]. Spinedi et al. [168] showed that exposure 
of CHP-100 neuroepithelioma cells to increasing concentrations of 
NOE induced apoptosis of these cells by inhibiting acid ceramidase 
and glucosylation of naturally occurring ceramides. Tavarini et al. 
[169] treated SH-SY5Y neuroblastoma cells and showed the effect 
of NOE on cell viability. In another report, C6 glioma cells were 
pretreated with NOE and NOE increased the apoptotic effects of 
 
Fig. (4). Chemical structures of ceramidase inhibitors and their analogs. 
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cisplatin. Furthermore, NOE made cisplatin-resistant cells sensitive 
to cisplatin [170]. NOE-mediated pharmacological inhibition of 
acid ceramidase increased ceramide generation in hepatoma cells 
such as HepG2, Hep-3B, SK-Hep and Hepa1c1c7 and, sensitized 
them to daunorubicin-induced cell death. NOE also reduced tumor 
growth in vivo in a murine model of hepatocellular carcinoma 
[171]. NOE was also found to be effective against sarcoma and 
neuroectodermal tumor cell lines and treatment with NOE sensi-
tized these cells to fenretinide-induced apoptosis [45]. Although 
NOE has been used in various basic studies, it is excluded from any 
therapeutic use due to its low potency and pure selectivity [172]. 
(2R,3Z)-N-(1-hydroxyoctadec-3-en-2-yl) pivalamide (DM102), an 
acid ceramidase inhibitor, was shown to decrease cell viability in 
A549 human lung adenocarcinoma cells in dose-dependent manner 
and cause cell cycle arrest at G1 [173]. In a recent study, DM102 
showed synergistic effects when applied together with fenretinide 
[4-HPR] to PC-3 and DU 145 hormone-refractory human prostate 
cancer cells. This combination increased caspase activity, ceramide 
and ROS levels [174]. Flowers et al. [175] examined apoptotic 
effects of C6-ceramide, DM102 and their combinations in human 
breast cancer cells and found that C6-ceramide-DM102 combina-
tion triggered apoptosis via activation of capsase 3/7, mitochondrial 
membrane depolarization and ROS production. 
Several ceramidase inhibitor analogs have been developed re-
cently in order to improve the activity of ceramidase inhibitors 
described in this study. LCL204, a lysomotropic analog of B13, 
was designed and synthesized by Holman et al. [158]. LCL204 
increased ceramide and decreased sphingosine levels in DU-145 
prostate cancer cells, and thereby LCL204 might function as a 
novel treatment option for prostate cancer [158]. In addition, this 
compound sensitized head and neck squamous (HNSCC) cells to 
Fas-induced apoptosis both in vitro and in a xenograft model. 
Therefore, Fas ligand and LCL204 combination therapy may be a 
new approach for advanced-stage head and neck cancer [157]. 
LCL385, another analog of B13, was shown to increase the sensi-
tivity of PPC-1 prostate cancer cells to radiation and significantly 
decrease tumor size in tumor xenografts generated in nude mice 
[176]. Bai et al. [177] designed a second generation B-13 analog, 
LCL 464, and investigated its apoptotic effects on MCF-7 cells. 
Compared with LCL204, it showed greater inhibition of acid cera-
midase in living cells. Lee et al. [178] synthesized and investigated 
the cytotoxic effects of twenty-one B13 sulfonamides on both 
colon cancer HT-29 and A-549 lung cancer cells. Some B13 sul-
fonamides showed more toxicity on both cells when compared with 
B13. In another study, novel NOE analogs were synthesized and 
their acid ceramidase inhibitory potentials were evaluated on cul-
tured cells. Some of these synthesized compounds showed inhibi-
tory effects and might be considered as novel acid ceramidase in-
hibitors [172]. 
2.5. Synthetic Ceramide Analogs 
There is a strong relationship between ceramides and apoptosis 
in cancer cells [179]. Therefore, increasing the concentration of 
intracellular ceramide can be an appropriate strategy for effective 
treatment of cancer. One of the possible strategies includes the 
treatment of cancer cells with exogenous synthetic ceramide ana-
logs Fig. (5) or mimetics that were shown to mimic endogeneous 
ceramide in terms of inducing apoptosis in a variety of cancer lines. 
Natural ceramide is unable to pass through the cell membrane, 
so it can not be used directly for cancer therapy [180]. Therefore, 
numerous ceramide analogs with unique properties have been de-
veloped. They include cell-permeable, short chain ceramides, ana-
logs with additional double bonds, analogs containing disulfide 
linkages, conjugates of ceramides and dihydroceramides [181, 182]. 
Some of them have improved solubility, easier cellular uptake and 
the ability to be localized in different compartments such as mito-
chondria and lysosomes in the cell. Some are responsible for induc-
ing mitochondrial apoptosis, consuming cellular glutathione and 
causing cytotoxicity in malignant cells [13]. In almost all studies, 
compared to long-chain (C18-C24) ceramides, short- and medium- 
chain ceramide analogs, C2 (N-acetyl-sphingosine), C6 (N-
hexanoyl-sphingosine), or C8 (N-octanoyl-sphingosine) ceramides 
have been more commonly used due to their solubility in cell 
growth medium and easy enterance into the cell [183]. 
 
Fig. (5). Structures of current ceramide analogs. 
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C2-, C6-, and C8-ceramide analogs have been shown to in-
duce apoptosis in human CEM-C7H2 acute lymphoblastic T-cell 
leukemia cells [184]. Kuroki et al. [185] investigated the effects of 
C2-ceramide on the growth of TNF-alpha-resistant B lymphoma 
Raji cells together with TNF-alpha-sensitive myeloid leukemia cells 
(HL-60 and U-937). C2-ceramide caused apoptotic cell death in 
HL-60 and U-937 cells, but did not induce apoptosis in Raji cells. 
C2-ceramide mediated growth inhibition in Raji cells was found to 
be related with cell cycle arrest in G0/G1 [185]. In some studies, 
the relationship between ceramide analogs and caspases were de-
termined. For instance, treatment of Jurkat cells with C2-ceramide 
activated caspase-3 and -7 that subsequently cleaved poly (ADP-
ribose) polymerase (PARP) [186]. In another report, time- and 
dose- dependent cell death induced in HL-60 cells treated with C2-
ceramide and its homologs were due to DNA fragmentation, prote-
olytic cleavage of pro-caspase-3 and the cleavage of PARP [187]. 
Selzner et al. [165] displayed the apoptotic effects of C2- and C6- 
ceramide in SW-403 human colon cancer cells. Fillet et al. [188] 
clearly demostrated that C2- and C6- ceramides activated NF-?B, 
induced caspase-3 activity, PARP cleavage and cyctochrome c 
release in both human colon carcinoma cells and ovarian carcinoma 
cells whereas C16-ceramide did not enter into these cells.  
The cell death related effects of ceramide analogs have been 
shown to be against a variety of cancer cell lines. Recently, signifi-
cant attention has been paid to the potential usage of ceramide ana-
logs as adjuvants with conventional chemotherapeutic agents. Char-
les et al. [189] showed the induction of apoptosis more effectively 
in MDA-MB-468 human breast cancer cells that were treated with 
taxol C6-ceramide combination. C6-ceramide increased the apop-
totic effects of doxorubicin in multiple cell lines including MCF-7 
via activation of AMP-activated protein kinase (AMPK), mTOR 
inhibition and Bcl-2 downregulation [190]. Our group is also inter-
ested in the apoptotic roles of ceramide in several different cancer 
types. For instance, Gencer et al. [118] examined the therapeutic 
potentials of C8-ceramide in combination with dasatinib in K562 
and Meg-01 chronic myeloid leukemia cells and showed that ex-
ogenous C8-ceramide application increased the apoptotic effects of 
dasatinib. In one of our studies we found that the sensitivity of hu-
man chronic myeloid leukemia cells increased to nilotinib via co-
administration of C8-ceramide [117]. Combination of C:8 ceramide 
increased the antiproliferative and apoptotic effects of resveratrol 
on chronic myeloid leukemia [114] and acute myeloid leukemia 
[115] cells while combination of docetaxel with C8:ceramide 
showed significant synergistic apoptosis on prostate cancer cell 
lines [119]. In a recent report, Zhu et al. [191] investigated the syn-
ergistic effects of histone deacetylase inhibitor, TSA, and C6-
ceramide both in vitro and in vivo pancreatic and ovarian cancer 
models. TSA in combination with C6-ceramide induced apoptosis 
by inhibiting AKT and hyperacetylating ?-tubulin. 
Several structural ceramide analogs as well as short-chain ce-
ramides (C2, C6 and C8) have been developed and shown to induce 
apoptosis in a variety of cancer lines. For instance, Karasawas et al. 
[192] showed the apoptotic potential of C8-ceramide stereoisomers, 
N-octanoyl-DL-erythrodihydrosphingosine (DL-e-DHC8-Cer) and 
N-octyl-D-erythro-sphingosine (D-e-C8-Ceramine), which have an 
amine instead of an amide bond, on U-937 leukemia cells. FS-5, 
another structural analog, induced apoptotic cell death in Molt-4 
leukemic cells [193]. Ceramide analogs, C16-serinol and C18-
serinol, were shown to trigger apoptotic signaling pathways in 
human neuroblastoma, glioma, medulloblastoma, and adenocarci-
noma cells [67, 66]. The properties of these ceramide mimetics 
such as tumor specificity, increased water solubility, rapid uptake 
and slow release from the cells make them potential candidates for 
cancer therapy [66]. Crawford et al. [194] found that novel cera-
mide analogs, 5R-OH-3E-C8-ceramide, adamantyl-ceramide 
and benzene-C4-ceramide, showed increased cytotoxicity against 
drug-resistant breast tumor cells, SKBr3 and MCF-7/Adr, compared 
with normal breast epithelial cells. 4,6-diene-Cer, a novel ceramide 
analog, was effective in inducing apoptosis in MCF-7 breast cancer 
cells by causing the release of cytochrome c and a decrease in the 
mitochondrial membrane potential [195]. The cationic C8-
ceramide analog has been shown to inhibit clonogenic survival and 
induce apoptosis in endocrine-resistant MDA-MB-231 and 
chemoresistant MCF-7 TN-R breast cancer cells [196]. Ha et al. 
[197] synthesized several ceramide analogs and showed that these 
analogs exhibited potent antileukemic activities against human 
leukemia HL-60 cells by causing DNA fragmentation. Novel cera-
mide analogs, AD2646 and AD2687, induced cell death in Jurkat 
leukemic cells both by caspase -dependent and - independent path-
ways [198]. Dagan et al. [199] found that three different ceramide 
analogs, AD2646, AD2672 and AD2665, had cytotoxic and apop-
totic effects on HL-60 leukemic cells. To clarify the relationship 
between ceramide-induced cell death and mitochondria, positively 
charged ceramides have been developed and shown to increase 
mitochondrial inner membrane permeability and cause the release 
of cytochrome c by activating specific ion transporters like H+ 
transporter [200, 201]. Senkal et al. [202] determined the growth-
inhibitory function of a highly soluble cationic pyridinium cera-
mide, L-threo-C6-pyridinium-ceramide-bromide (LCL-124), alone 
and in combination with gemcitabine in HNSCC cells and HNSCC 
tumors in SCID mice. Combination therapy resulted in increased 
tumor suppression in mice via inhibition of telomerase activity and 
caused a decrease in telomere length. In addition, such novel 
pyridinium ceramides have been shown to cause cell cycle arrest in 
G0/G1 together with inhibiton of telomerase activity [203]. LCL-
29, D-erythro isomer of LCL-24, was applied to mouse SCCVII 
squamous cell carcinoma tumors in combination with Photofrin-
Photodynamic therapy (PDT). Although LCL-29 had no effect on 
tumor growth alone, tumor growth retarded by PDT was enhanced 
by LCL-29 [204, 205]. Dindo et al. [206] characterized the effects 
of the newly synthesized cationic long chain-ceramide, LCL-30, in 
SW403 cells and showed that LCL-30 specifically accumulated in 
the mitochondria and induced apoptosis by the mitochondrial path-
way. LCL-30 was firstly tested in an in vivo model of metastatic 
colorectal cancer by Dahm et al. [207]. LCL-30 caused a reduction 
in the proliferative activity and the growth of the established tumor 
in BALB/c mice. Positive charge of such ceramide analogs is re-
sponsible for their targeting and accumulation especially into mito-
chondria (sometimes into nucleus) of cancer cells which have been 
shown to acquire a higher negative membrane potential compared 
with normal cells [208]. 
Cell permeable ceramide analogs may show reduced efficieny 
due to their hydrophibicity and precipitation when applied in aque-
ous solutions [183]. To overcome such problems, it is important to 
develop novel delivery methods to increase the intracellular cera-
mide accumulation. Stover et al. [209] described the liposomal 
delivery of C6-ceramide into MDA-MB-231 breast cancer cells and 
results were compared with nonliposomal administration of cera-
mide. These targeted C6-ceramide can regulate Akt phosphoryla-
tion and activate caspase 3/7 more effectively. Moreover, pegylated 
liposomal formulation of C6-ceramide was delivered systemically 
into a syngeneic BALB/c mouse model of breast adenocarcinoma. 
The results indicated that liposomal C6-ceramide treatment caused 
a dose-dependent inhibition of tumor growth as compared with 
untreated controls [70]. In another study, polymeric nanoparticle-
coated C6-ceramide was introduced into a multidrug-resistant 
SKOV-3 ovarian cancer cells together with paclitaxel to induce 
apoptotic cell death and overcome multidrug resistance [210]. 
2.6. Ceramide Kinase Inhibitors 
Ceramide-1-phosphate (C1P) is a significant signaling molecule 
that activates cell survival and proliferation while blocking apopto-
sis, thereby C1P and ceramide are antagonistic molecules that can 
be converted into each other by kinase and phosphatase enzymes 
[211, 212]. 
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Table 1. Overview of GCS Inhibitors 
 
Preclinical Studies Clinical Phase Studies 
Compound 
In vitro Studies Animal Studies  
PPMP 
Acute lymphoblastic leukemia, chronic 
myeloid leukemia, acute promyelocytic 
leukemia, breast cancer, cervix cancer, 
histiocytic lymphoma, neuroblastoma, 
lung cancer, melanoma, colon cancer, 
prostate cancer, osteosarcoma 
  
PDMP 
Chronic myeloid leukemia, acute pro-
myelocytic leukemia, breast cancer, 
neuroblastoma, glioma, colon cancer, 
prostate cancer 
Colon cancer, chronic myeloid leukemia  
PPPP Hepatoma, neuroblastoma   
Genz-123346 
Colon cancer, hepatocellular carcinoma, 
cervical cancer 
  
NB-DNJ Melanoma, neuroblastoma   
OGT2378 Melanoma Melanoma  
 
Table 2. Overview of SK Inhibitors and S1PR Inhibitors 
 
Preclinical Studies Clinical Phase Studies 
Compound 
In vitro Studies Animal Studies  
SKi 
Breast cancer, prostate cancer, chronic 
myeloid leukemia, acute promyelocytic 
leukemia 
  
ABC294640 
Kidney carcinoma, hepatoma, mammary 
adenocarcinoma, prostate cancer 
Kidney carcinoma, hepatoma, breast 
cancer 
 
BML258 
Histiocytic leukemia, acute T-cell leuke-
mia, acute myelogenous leukemia 
Acute myelogenous leukemia  
FTY720 
Breast cancer, myeloma, leukemia, 
melanoma 
Melanoma, breast cancer, leukemia  
DMS Colon cancer   
PF543 Head and neck cancer   
DHS 
Solid tumors including adrenal cortical 
cancer, liver cancer, lung cancer 
Solid tumors Solid tumors 
VPC03090 Mammary cancer Mammary cancer  
LT1002 
Breast cancer, ovarian cancer, lung 
adenocarcinoma 
Breast cancer, ovarian cancer, lung 
adenocarcinoma 
 
LT1009 Ovarian cancer Breast cancer, ovarian cancer 
Colorectal cancer, breast cancer, ovarian 
cancer, renal cancer, prostate cancer, 
head and neck cancer 
 
Table 3. Common Analogs and Inhibitors of Ceramide Metabolism 
 
Compound Mechanism Preclinical Studies 
D-MAPP Alkaline ceramidase inhibitor 
In vitro studies: melanoma, promyelocytic leukemia, 
squamous cell carcinoma cells 
Animal studies: not studied 
B13 Acid ceramidase inhibitor 
In vitro studies: colorecteral, prostate cancer cells 
Animal studies: mice xenografts of colon and prostate 
cancer 
NOE Acid ceramidase inhibitor 
In vitro studies: Hepatoma, glioma, sarcoma cells 
Animal studies: murine model of hepotacellular carci-
noma 
Short-chain ceramides (C2-C6-, C8-ceramide) Ceramide analog 
In vitro studies: Acute lymphoblastic T-cell leukemia, 
breast, chronic myeloid leukemia, ovarian cancer cells 
Animal studies: mice xenografts of pancreatic and 
overian cancer, mouse model of breast cancer 
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(Table 3) contd….. 
Compound Mechanism Preclinical Studies 
C16-serinol and C18-serinol Ceramide analog 
In vitro studies: neuroblastoma, glioma, adenocarci-
noma cells 
Animal studies: not studied 
Adamantyl-ceramide Ceramide analog 
In vitro studies: Breast cancer cells 
Animal studies: not studied 
4,6-diene-Cer Ceramide analog 
In vitro studies: Breast cancer cells 
Animal studies: not studied 
Cationic pyridiniumceramide Mitochondrial targeting 
In vitro studies: HNSCC, squamous cancer, colon 
cancer cells 
Animal studies: HNSCC tumor model and colon cancer 
model in mice 
K1 Ceramide kinase inhibitor 
In vitro studies: basophilic leukemia cells 
Animal studies: not studied 
NVP-231 Ceramide kinase inhibitor In vitro and animal studies: Not studied 
* Clinical phase studies have not been performed yet for these inhibitors and anologs. 
 
 
Fig. (6). Stuctures of novel ceramide kinase inhibitors. 
Based on the relationship between cancer and ceramide kinase 
(CerK), inhibition of CerK may be a promising strategy in cancer 
therapies, especially to enhance the efficacy of anti-cancer therapies 
such as drugs, radiation and immunotherapy [213]. 
Specific CerK inhibitors Fig. (6) have been characterized in 
only a few studies with different assay procedures and they are just 
in their first decade [214, 215]. K1 was found to function as a non-
competitive CerK inhibitor and caused a partial inhibition of CerK 
and C1P production without any effect on cell growth in RBL-2H3 
cells [216]. Munagala et al. [214] identified and characterized sev-
eral potential CerK inhibitors using a chemiluminescence based 
assay. The first potent competitive CerK inhibitor was identified by 
Graf et al. [217] and it was called NVP-231, adamantane-1-
carboxylic acid [2-benzoylamino-benzothiazol-6-yl] amide. NVP-
231 was found to be highly specific for CerK and to function effi-
ciently both in vitro and in cell-based assays. The combination of 
NVP-231 with tamoxifen increased the ceramide levels in a cellular 
system [213, 215]. Another CerK inhibitor, NVP-995, was found to 
be less potent and used as a control in cellular assays [215].  
3. CONCLUSION AND FUTURE PERSPECTIVES 
Sphingolipids are vital constituents of the cells, and play sig-
nificant roles in the regulation of various cellular processes, most 
importantly in cell proliferation, cell differentiation and pro-
grammed cell death. Therefore, dysregulation of the sphingolipid 
metabolism leads to oncogenesis, tumor progression and drug resis-
tance. Targeting the elements of sphingolipid metabolism appears 
to be important for the development of novel anti-cancer therapeu-
tics or to increase the effectiveness of the current treatment strate-
gies. Different approaches mainly aim to up-regulate the levels of 
apoptotic sphingolipids such as ceramides and sphingosine, while 
the proliferative ones including C1P, S1P and GluCer are down-
regulated. Delivery of the cytotoxic sphingolipids like short chain 
ceramide analogs to the tumor cells can also be considered in order 
to establish chemotherapeutic intervention. In other words, manipu-
lation of sphingolipid metabolism is considered to be a good ap-
proach for development of novel therapies. It is believed that a 
combination therapy with conventional cytotoxic drugs while in-
creasing the levels of pro-apoptotic ceramide can be more benefi-
cial [116-119]. However, because apoptotic sphingolipids may 
cause cytotoxicity in non-cancerous cells, delivering cytotoxic spe-
cies specifically to the malignant cells remains as an important 
issue that should be concentrated on. For this reason, research con-
ducted in the cell culture should be carried further, and more in vivo 
experiments are needed to be conducted. By this way, the actual 
potential of sphingolipid metabolism as an anti-cancer treatment 
regimen will be discovered. In the light of the growing literature in 
this area, it is suffice to say that sphingolipid metabolism holds a 
great promise for the future treatments of multiple cancer types. 
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